-
The Interim Acceptance and Ultraorphan Pathways in Scotland: An Update
Sep 9, 2025, 16:22 PM -
Adherence to Anti-VEGF Treatment of Patients With Age-Related Macular Degeneration of Exudative Type (nAMD) and Diabetic Macular Edema (DME) in Greece: Evidence From an Expert Panel
Sep 9, 2025, 16:22 PM -
Real-World Uptake of SGLT2i Usage in Patients With Chronic Kidney Disease or Heart Failure: A German Claims Data Analysis
Sep 9, 2025, 16:22 PM -
Comparative Analysis of Safety of Targeted NSCLC Therapies Using the FDA Adverse Event Reporting System (FAERS) Differing Experience of Healthcare Providers (HCP) From EU vs. US
Sep 9, 2025, 16:22 PM -
Systematic Review of Real-World Data on the Effectiveness and Safety Profiles of First-Line Therapies in Chronic Lymphocytic Leukemia
Sep 9, 2025, 16:22 PM -
A NICE Idea? Assessing the Impact of the Severity Modifier in Oncology and Nononcology Single Technology Appraisals
Sep 9, 2025, 16:22 PM -
The Effect of Pharmaceutical Pricing Policies on Healthcare Expenditures in Turkey: Analysis for the Period 2015-2024
Sep 9, 2025, 16:22 PM -
Knowledge and Awareness of Primary Care Physicians (PCPs) Towards Respiratory Syncytial Virus (RSV) in Australia, Hong Kong, Japan, New Zealand, South Korea, Singapore, and Taiwan
Sep 9, 2025, 16:22 PM -
A Disease Progression Model Comparing Respiratory and Motor Decline in People With Late-Onset Pompe Disease Treated With Cipaglucosidase Alfa Plus Miglustat vs. Alglucosidase Alfa
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness of Pegcetacoplan for the Treatment of Paroxysmal Nocturnal Hemoglobinuria in Patients With Treatment Failure After C5 Inhibitor Therapy: An Analysis From the Brazilian Public Healthcare System Perspective
Sep 9, 2025, 16:22 PM -
Applying the Evidence-Generation Continuum Concept to Support Patient Access to Innovative Therapies in France: A Use Case in Rare Diseases
Sep 9, 2025, 16:22 PM -
Rescaled Tariff Regression for EQ-5D-5L Health State Valuation: An Equivalent Alternative to the Nonparametric Crosswalk
Sep 9, 2025, 16:22 PM -
Cost-Utility Analysis of Pegunigalsidase Alfa Compared to Agalsidase Alfa and Agalsidase Beta for the Treatment of Adult Patients With Fabry Disease in Greece
Sep 9, 2025, 16:22 PM -
A Gap Analysis of HTA Methods in Europe: Results From SUSTAIN-HTA
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness Analysis of Intermittently Scanned Continuous Glucose Monitoring in Individuals With Type 2 Diabetes Using Insulin in Sweden: A National Real-World Evidence Perspective
Sep 9, 2025, 16:22 PM -
Long-Term Impact of Emicizumab in Hemophilia A (HA): Analysis by Inhibitor Status in Three Latin American (LATAM) Countries
Sep 9, 2025, 16:22 PM -
Burden of In-Clinic and At-Home Administration of Injectable Biologics for Severe Asthma and Chronic Rhinosinusitis With Nasal Polyps: Interim Results From a Time and Motion Study
Sep 9, 2025, 16:22 PM -
Projected Public Health Impact of Synchronized COVID-19 and Influenza Vaccination With a Combination Vaccine in US Older Adults
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness of Etrasimod, Ozanimod, and Adalimumab Compared to Infliximab in Treatment-Naive Patients With Moderate to Severe Ulcerative Colitis
Sep 9, 2025, 16:22 PM -
Transferable Exclusivity Extension Vouchers for Antimicrobials: Incentive Design, Implementation Challenges, and Policy Trade-offs
Sep 9, 2025, 16:22 PM